NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
Clinical Trials
13 trialsNCT04529850 2022-08-16
Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer
Galera Therapeutics, Inc.
Phase 2 Completed
NCT02399228 2021-11-19
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis
Santalis Pharmaceuticals, Inc.
Phase 2 Completed
NCT01403064 2021-05-11
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
CSL Behring
Phase 2 Terminated
NCT03234465 2020-11-23
Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day
Oragenics, Inc.
Phase 2 Terminated
NCT02324335 2019-01-16
Brilacidin
Innovation Pharmaceuticals, Inc.
Phase 2 Completed
NCT00031551 2017-12-06
Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02013050 2017-08-28
A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
Soligenix
Phase 2 Completed
NCT01898091 2017-03-06
OM
Medical University of South Carolina
Phase 2 Completed
NCT00189488 2014-09-15
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
Swedish Orphan Biovitrum
Phase 2 Completed
NCT00698204 2014-06-05
Cox-2 Inhibition in Radiation-induced Oral Mucositis
UConn Health
Phase 2 Completed
NCT00267046 2012-05-16
Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00385515 2009-05-07
Efficacy of SNX-1012 in the Treatment of Oral Mucositis
Mucosal Therapeutics
Phase 2 Completed